Evaluator Blind, Controlled, Preliminary Clinical Study of Telitacicept in the Treatment of Diffuse Systemic Sclerosis With Progressive Skin Progression
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Telitacicept (Primary)
- Indications Diffuse scleroderma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Aug 2024 New trial record